My watch list  


News Pioglitazone

  • New strategy may drop cancer's guard

    A drug used now to treat Type 2 diabetes may someday help beat breast and ovarian cancers, but not until researchers decode the complex interactions that in some cases help promote tumors, according to Rice University scientists. Rice bioscientist Daniel Carson and alumna Micaela Morgado researched more

  • Diabetes medication reduces dementia risk

    Treating people with type 2 diabetes, also known as "age-related diabetes" with antidiabetics reduces their risk for Alzheimer’s and other types of dementia. The risk is most significantly reduced by the drug pioglitazone. Researchers of the German Center for Neurodegenerative Diseases (DZNE) draw t more

  • Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan

    Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV (DPP-4) in more

All news on pioglitazone

Publications Pioglitazone

All publications on pioglitazone


Pioglitazone Pioglitazone is a prescription drug of the class thiazolidinedione with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA and Glustin in Europe by the pharmaceutical co ... more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE